Well, considering the following that just happened recently to Optimer, I guess this is a real possibility minus Astellas as Bayer already has rights in Japan, but Bayer could very well be substituted.
Just goes to show, big Pharma is shopping (however, GSK pulled out of Optimer). The only downside to TSRX is it's a year out from revenue, the purchase of Optimer would bring revenue the moment the deal is done... so that is one benefit OPTR has over TSRX.
May 14, 2013
"Bloomberg reported that GlaxoSmithKline, Cubist Pharmaceuticals, AstraZeneca, and Japan's Astellas Pharma were all interested in picking up Optimer. If the reports are correct, that's quite a lineup of potential suitors. Bloomberg went on to add that Optimer hopes to get as much as $1 billion in an auction. That figure would price the company's shares around $18, significantly higher than they are now."